

Supplementary material to

Anti-amyloid activity of carrageenan-loaded liposomal nanocarriers against subcutaneous insulin-induced amyloid masses in rats

Iman Saranya Udayakumar¹ , Koyeli Girigoswami² , Venkatakrishnan Kiran¹ ,
Devadass Jessy Mercy¹ , Vijayashree Raghavan³  and Agnishwar Girigoswami¹ 

¹Medical Bionanotechnology, Faculty of Allied Health Sciences, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, TN-603103, India

²Medical Bionanotechnology Lab, Department of Obstetrics and Gynaecology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, TN-602105, India

³Department of Pathology, Vels Medical College and Hospital, Manjankaranai, Chennai, TN-601102, India

ADMET & DMPK 14 (2026) 3536; <https://doi.org/10.5599/admet.3536>

Histopathological observation




Figure S1. Histopathological observation of drug injected on subcutaneous tissue (A) CG treated, (B) nCG treated




Figure S2. Histopathological observation of major organs across experimental groups (G1-G7). Green arrows indicate mild congestion, red arrows indicate inflammation, blue arrows indicate tubular damage, and yellow arrows indicate coagulative necrosis

Table S1. The average body weight of rats treated with all samples was measured at a 7-day interval

Treatment groups	Rats body weight, g				
	Day 1	Day 7	Day 14	Day 21	Day 28
CG (Dose B)	333.6±10.03	323.6±4.80	327.6±4.50	333±4.91	336±5.05
nCG (DoseB)	357.6±9.58	366±9.29	365±12.4	379±12.5	387±13.2
IA	374±9.70	382.5±7.87	384±8.34	398.5±9.57	385±11.3
IA+CG (Dose A)	360.3±9.4	355.6±8.87	373±5.37	356±8.88	385.5±6.25
IA+CG (Dose B)	366±10.06	363±6.85	373.6±7.55	376±11.1	386.3±2.2
IA+nCG (Dose A)	371.6±8.7	365±6.51	370±5.77	374.3±10.4	383.310.4
IA+nCG (Dose B)	333.6±15.01	323.6±10.64	327.6±12.3	333±11.2	336±10.6

Table S2. The average feed intake of rats treated with all samples was measured at a 7-day interval

Treatment groups	Feed intake, g				
	Day 1	Day 7	Day 14	Day 21	Day 28
CG (Dose B)	10.2±0.56	8.6±0.28	10±0.14	9.28±0.19	13.3±0.21
nCG (DoseB)	10.3±0.21	8.9±0.21	8.7±0.07	9.6±0.14	17.5±1.06
IA	11.8±0.14	8.3±0.49	8.8±0.4	8.7±0.42	8.4±0.28
IA+CG (Dose A)	10.2±0.14	10.2±0.14	10.2±0.14	16.7±1.20	11±0
IA+CG (Dose B)	9.6±0.42	8.88±0.19	12.11±0.07	14.9±0.42	8.11±0.07
IA+nCG (Dose A)	10.4±0.42	7±0.70	10.28±0.19	17.4±0.28	17.8±0.56
IA+nCG (Dose B)	10.4±0.28	10.17±0.12	11.94±0.66	10.57±0.40	11.1±0.58

Table S3. The average water intake of rats treated with all samples was measured at a 7-day interval

Treatment groups	Water intake, g				
	Day 1	Day 7	Day 14	Day 21	Day 28
CG (Dose B)	15.7±0.49	12.8±0.56	22.8±0.56	20.4±1.69	13.5±0.35
nCG (DoseB)	15.7±0.70	19.8±0.56	15.5±0.35	17.8±0.56	14.7±0.49
IA	17.5±0.35	15.2±0.14	10.4±0.28	10.7±0.49	8.5±0.35
IA+CG (Dose A)	11.4±0.28	14.2±0.14	22.8±1.97	22.8±.97	10±1.41
IA+CG (Dose B)	14.2±0.14	20±0	15.7±0.49	16.4±0.28	14.2±2.26
IA+nCG (Dose A)	17.8±	15.4±0.28	20.2±1.55	30±1.41	17.8±0.14
IA+nCG (Dose B)	15.7±	19.8±0.56	35.5±3.88	34.2±0.84	22.4±0.42